QuidelOrtho (NASDAQ:QDEL) Reaches New 1-Year Low – What’s Next?

QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report)’s share price reached a new 52-week low during trading on Tuesday. The stock traded as low as $9.82 and last traded at $9.9670, with a volume of 994,067 shares changing hands. The stock had previously closed at $10.21.

Analyst Upgrades and Downgrades

QDEL has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, October 15th. Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $13.62.

Check Out Our Latest Report on QDEL

QuidelOrtho Stock Performance

The business’s fifty day moving average is $12.10 and its 200-day moving average is $15.26. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 1.40. The company has a market cap of $612.03 million, a PE ratio of -1.65 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.13. QuidelOrtho had a negative net margin of 14.24% and a positive return on equity of 3.22%. The business had revenue of $618.90 million for the quarter, compared to the consensus estimate of $627.83 million. During the same period last year, the firm earned $0.80 earnings per share. The company’s quarterly revenue was down 11.6% on a year-over-year basis. As a group, research analysts predict that QuidelOrtho Corporation will post 0.66 EPS for the current fiscal year.

Institutional Trading of QuidelOrtho

A number of hedge funds and other institutional investors have recently bought and sold shares of QDEL. Algert Global LLC purchased a new position in shares of QuidelOrtho in the third quarter worth $1,057,000. Goldman Sachs Group Inc. increased its holdings in QuidelOrtho by 109.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,234,367 shares of the company’s stock valued at $23,550,000 after acquiring an additional 1,169,623 shares during the last quarter. Lighthouse Investment Partners LLC lifted its stake in QuidelOrtho by 295.5% in the 3rd quarter. Lighthouse Investment Partners LLC now owns 42,197 shares of the company’s stock worth $445,000 after purchasing an additional 31,527 shares in the last quarter. Findell Capital Management LLC purchased a new stake in QuidelOrtho in the 3rd quarter worth $4,743,000. Finally, Soleus Capital Management L.P. bought a new position in shares of QuidelOrtho during the 3rd quarter valued at about $211,000. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

(Get Free Report)

QuidelOrtho Corporation develops and manufactures diagnostic testing products used in healthcare settings. Its offerings include tests and instruments for immunoassay, molecular diagnostics, clinical chemistry, and transfusion medicine, as well as rapid tests designed for point-of-care use. The company serves hospitals, clinical laboratories, blood banks, physician offices, and other healthcare providers. Its product lines include the VITROS clinical laboratory systems, ORTHO VISION blood-bank analyzers, and Sofia rapid diagnostic platforms.

Further Reading

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.